Chronic allograft nephropathy by Fletcher, Jeffery T. et al.
EDUCATIONAL REVIEW
Chronic allograft nephropathy
Jeffery T. Fletcher & Brian J. Nankivell &
Stephen I. Alexander
Received: 22 February 2008 /Revised: 31 March 2008 /Accepted: 17 April 2008 /Published online: 27 June 2008
# IPNA 2008
Abstract Chronic allograft nephropathy (CAN) is the lead-
ing cause of renal allograft loss in paediatric renal transplant
recipients. CAN is the result of immunological and non-
immunological injury, including acute rejection episodes,
hypoperfusion, ischaemia reperfusion, calcineurin toxicity,
infection and recurrent disease. The development of CAN is
often insidious and may be preceded by subclinical rejection
in a well-functioning allograft. Classification of CAN is
histological using the Banff classification of renal allograft
pathology with classic findings of interstitial fibrosis, tubular
atrophy, glomerulosclerosis, fibrointimal hyperplasia and
arteriolar hyalinosis. Although improvement in immunosup-
pression has led to greater 1-year graft survival rates, chronic
graft loss remains relatively unchanged and opportunistic
infectious complications remain a problem. Protocol biopsy
monitoring is not current practice in paediatric transplantation
for CAN monitoring but may have a place if new treatment
options become available. Newer immunosuppression regi-
mens, closer monitoring of the renal allograft and manage-
ment of subclinical rejection may lead to reduced immune
injuryleadingtoCANinthepaediatricpopulationbutmustbe
weighedagainst the riskofincreasedimmunosuppressionand
calcineurin inhibitor nephrotoxicity.
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Abbreviations
ACR acute cellular rejection
AHR acute humoral rejection
ANZDATA Australian and New Zealand Dialysis and
Transplantation Association
BKV BK virus
CAN chronic allograft nephropathy
CMV cytomegalovirus
CNI calcineurin inhibitors
EBV Epstein-Barr virus
MMF mycophenolate mofetil
NAPRTCS North American Pediatric Renal Trials and
Collaborative Studies
OKT3 orthoclone OKT3 (muromonab-CD3)
PTLD posttransplant lymphoproliferative disease
SCR subclinical rejection
Treg regulatory T cells
TGF-β transforming growth factor-beta
Introduction
Chronic allograft nephropathy (CAN) is a histopathological
diagnosisusedtodenotefeaturesofchronicinterstitialfibrosis
and tubular atrophy within the renal allograft. It remains the
most common cause of graft dysfunction and loss in children
following renal transplantation. The incidence and patholog-
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e-mail: Stephena@chw.edu.auical processes involved in chronic graft loss in children with
renal transplants appear similar to those found in adult renal
transplants. The term CAN replaced chronic allograft rejec-
tion.Previously,chronicallograftrejectionwasconsideredthe
major aetiological factor for chronic graft loss, as features of
cellular inflammatory immune infiltrates, identified on kidney
biopsies, were suggestive of injury from immunological
changes within the graft. This classification changed with
the implementation of the Banff 97 working classification of
renal allograft pathology criteria [1], which included features
of the Chronic Allograft Damage Index [2] and Co-
operative Clinical Trials in Transplantation systems. This
led to the standardisation and semiquantification of these
lesions. It was revised again in 2003 with the addition of
C4d, a cleavage product of activated complement factor 4, as
a marker of antibody-mediated injury [1, 3] and again in
2007 when the nonspecific deficits of sclerosing CAN was
replaced by the more accurate term interstitial fibrosis not
otherwise specified. These criteria all use histopathological
markers of renal transplant injury to define the level and
severity of allograft damage and selected specific features
that imply a specific diagnosis.
Histopathology
The histological features that define CAN in the kidney
transplant allograft include interstitial fibrosis and tubular
atrophy, as mentioned above, as well as features of glo-
merulosclerosis and fibrointimal hyperplasia (Fig. 1). CAN
is graded as mild, moderate or severe based on the severity
of chronic interstitial fibrosis and tubular atrophy and the
area of cortex affected in the biopsy specimen. Interstitial
fibrosis, denoted as ci, is scored by the area fibrosed and
ranges from mild (ci1 6–25%) to severe (ci3 >50%). Tubular
atrophy refers to the loss of tubular height and increased
luminal size of the tubules and is denoted as ct (ct0–ct3).
Tubular atrophy and interstitial fibrosis are often nonspecific
by themselves. Chronic transplant glomerulopathy refers to
the thickening of the glomeruli and is quantified by the per-
centage of glomeruli developing “double contours” of
peripheral capillary loops and is denoted as cg (cg0–cg3)
(Fig. 2a). Arteriolar hyalinosis, as suggested by the term,
denotes thickening of arterioles within the kidney based on
the amount of periodic-acid-Schiff-positive hyalinosis and is
denoted as ah (ah0–ah3), often implying calcineurin inhibitor
(CNI) nephropathy. More in-depth quantification of all of
these criteria is readily available [1].
The addition of C4d staining to the Banff criteria in 2003
has allowed for the supportive diagnosis of chronic antibody-
mediated rejection. C4d is a positive marker of complement
activation, implying the presence of antidonor antibodies and
hence antibody-mediated rejection. C4d is released on bind-
ing to antibody. These antibodies bind to endothelial cells in
glomerular and peritubular capillaries, suggesting antibody
deposition [4, 5]( F i g .2b) and prompting the clinician to
request donor-specific antibody testing. C4d staining is
regarded as positive or negative, and its position within the
biopsy is recorded and graded by type, as acute tubular
necrosis (ATN)-like, capillary or arterial [6]. C4d is gaining
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Fig. 1 Schematic illustration of biopsy of a renal allograft showing histopathological features characteristic of chronic allograft nephropathy (CAN).
Italics indicate potential precipitating factors for CAN associated with the areas they specifically target. Reprinted with permission from [51]
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[7] and has a role in acute rejection, early unexplained
primary graft nonfunction and chronic dysfunction, especial-
ly where transplant glomerulopathy is present [5].
The evidence for chronic allograft nephropathy as the
leading cause for progressive renal failure and graft loss is
supported by both transplant registry and protocol biopsy
data. Graft loss secondary to the progressive development of
CAN has consistently been recorded within the European,
North American (NAPRTCS) [8]a n dA u s t r a l i a n –New
Zealand (ANZDATA) transplantation registries. Although
histological confirmation of CAN by biopsy is variable,
reports from all databases show progressive transplant loss
attributable to CAN continuing to the present day despite
improved changes to immunosuppression regimens. Cohort
studies using protocol biopsies performed in child and adult
transplant recipients from day of transplant to 10 years
posttransplantation consistently demonstrate the evolution
and progression of CAN [9–16]. Larger studies have helped
identify aetiological factors involved in chronic graft injury.
In particular, the 10-year protocol biopsy study on adult
patients with kidney–pancreas transplants defined the occur-
rence of severe rejection, of subclinical rejection and in some
cases true chronic rejection, as evidenced by tubulointer-
stitial damage, with increasing evidence of progressive
nephropathy from CNIs. Histological lesions of grade 1
CAN present in up to 94.2% of adult patients at 1 year
posttransplant[11, 12], andgradesprogressivelyworsenupto
10 years. Protocol biopsy studies in children demonstrate
similar features of CAN [17–23]. The most recent of these,
with 245 biopsies in 81 children over 2 years, found
subclinical rejection (SCR) at 3 months and progressive
changes to CAN over 24 months [20].
Mechanisms of injury
CAN results from the accumulation of immune and nonim-
mune insults to the kidney. Numerous aetiological factors
have been implicated, including immunological factors, drug
toxicity, donor disease, recurrent disease and infections. The
immune mechanisms of acute rejection involve predominant-
ly direct antigen presentation, whereas previous episodes of
acute cellular rejection (ACR) and acute humoral rejection
(AHR) may leave residual injury that predisposes to CAN.
However, there is increasing evidence that chronic immune
injury may involve donor-derived peptides being indirectly
presented by host antigen-presenting cells leading to immune
sensitisation and damage. Other pathways may include
chronic humoral rejection with the presence of C4d, glomer-
ular changes and peritubular multilammination by electron
microscopy [4, 5]. Newer issues include certain innate path-
ways using the major histocompatibility complex (MHC)
class-I-related chain A (MICA) set of antigens, which have
now been implicated in acute rejection and may play a role
in CAN [24, 25]. Recent evidence suggesting the reduction in
regulatory T-cell (Treg) numbers, and inhibition of their
function by CNIs [26, 27] in human transplantation and
animal data suggesting that Tr e g sm a yh e l pt ol i m i tC A N[ 28],
may imply a protective role for Tregs in CAN development.
Aetiological factors of CAN
Donor factors
There are a number of donor factors associated with CAN,
which include: (1) donor age where extremes of donor ages
do poorly; (2) preexisting disease or injury to the donor; (3)
degree of HLA mismatch; (4) organ-specific issues such as
Fig. 2 a Renal allograft biopsy (silver staining) showing features of
transplant glomerulopathy with evidence of “double contours” in capillary
loops, mesangial proliferation and matrix expansion and basement
membrane thickening. b Renal allograft biopsy from a child with chronic
allograft nephropathy (CAN) showing C4d deposition (in brown)i n
peritubular capillaries consistent with humoral-mediated rejection
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(5) male donors have better outcomes than female donors
probably related to organ size; and (6) living related and
living unrelated donors have better outcomes than deceased
donors related to ischaemia reperfusion injury.
Recipient factors associated with CAN
In the recipient, age is again a risk factor, with younger child-
renbeingatgreaterriskforgraftloss,althoughNAPRTCSdata
suggest adolescence is associated with increased graft loss
largely from noncompliance [29]. Preexisting disease can
affect long-term outcome, with disease recurrence occurring
in conditions such as focal segmental glomerulosclerosis,
atypical haemolytic uraemic syndrome, congenital nephrotic
syndrome and immunoglobulin A (IgA) nephropathy. Prior
sensitisation from previous transplants, blood transfusions
and race, particularly African American recipients, are
associated with a poorer outcome. Small recipient size tran-
splanted with large adult-sized renal allografts—that is,
donor–recipient size discrepancy—has long been considered
a nonimmune risk factor for graft failure and CAN. Recent
evidence in a protocol biopsy study of such recipients on CNI
immunosuppression but no clinical episodes of rejection
identifiedSCRat3monthsandtheprogressionofhistological
changes of CAN to 24 months [20]. Whereas recognition of
the need to maintain early graft perfusion in small recipients
has led to a decline in early graft loss from thrombosis, pro-
tocol biopsy data suggests that ongoing chronic injury can
result from hypoperfusion of a large kidney in a small child.
Immune matching plays a role, with full HLA matching re-
ducing the risk of graft loss. In paediatrics, the presentation of
de novo antigens to children with recessive or X linked disease
receiving a kidney is an interesting concept suggested by the
protocol biopsies of children with congenital nephrotic syn-
drome,whichshowahighfrequencyofglomerulosclerosis[30].
Calcineurin inhibitors
The association of specific CNI changes leading to transplant
damage has been related to duration of exposure and dose in
protocol biopsy studies [11, 12]. Calcineurin use in children,
although improving first-year graft survival, has not led to a
marked improvement in long-term graft loss [8]. The one
randomised study of continued cyclosporine versus early
cyclosporine withdrawal with a 15-year follow-up suggested
that whereas CNIs provide a greater benefit initially, there is
then a greater progressive decline in graft function related to
CNI toxicity [31]. The mechanism of CNI toxicity may involve
the induction of transforming growth factor-beta (TGF-β)i n
renal tubular cells by CNI, leading to progressive fibrosis [32].
Specific histological features of CNI toxicity including
striped fibrosis and arteriolar hyalinosis are identified as early
as3monthsposttransplantandareoneofthemajorcontributors
to the development of CAN, with 100% of adult transplant
recipients showing some histological evidence of CNI toxicity
by 10 years posttransplant [11]. The only paediatric CNI-free
regimen, the CN-01 study [23] involving induction with
sirolimus, anti-CD25 monoclonal antibody and maintenance
prednisone, sirolimus and mycophenolate mofetil (MMF),
identified no evidence of interstitial fibrosis and tubular
atrophy in 12-month protocol biopsies of children who did
not experience rejection at 12 months. CNI reduction studies
in children maintained on MMF [33, 34]o rM M F
introduction in children with histological CAN [35–37]
showed renal function stabilisation but have not yet reported
histological data showing the slowed progression of CAN
and further long-term follow-up [33]. However, study
protocols that minimise immunosuppression may result in
higher rates of SCR and ACR and progression to CAN [19],
whereas those that use greater initial immunosuppression run
the risk of infectious complications and posttransplant
lymphoproliferative disease (PTLD) [23].
Infection
With the new powerful immunosuppressive regimens,
infectious complications after transplantation are the lead-
ing cause of paediatric hospital admission [38]. The major
viruses leading to admission and of increasing concern as
precipitating factors for chronic renal injury are Epstein-
Barr virus (EBV), cytomegalovirus (CMV) and BK virus
(BKV). As the incidence of positive donors to negative
recipients increases in paediatric transplant recipients, the
risk of viral reactivation in the graft and primary infection is
likely to increase. BKV nephropathy, for example, can lead
to graft loss in 50% of patients within 2 years [39], though
improved antiviral prophylaxis and treatment for posttrans-
plant viral infections—such as ganciclovir for CMV and
leflunomide, ciprofloxacin and cidofovir for BKV nephro-
pathy—have improved acute disease outcome. However,
little data are available on the efficacy of their use in
reducing the risk of CAN. EBV-associated PTLD managed
by reduction in immunosuppression and anti-CD20 mono-
clonal antibody (rituximab) has improved patient and
disease outcome [40], but progression to CAN is more rapid
following EBV disease.
Compliance
Adolescent transplant recipients may be noncompliant, and
children are at greater risks of variations in the immunosuppres-
sion related to this [41]. Compliance and kidney function has
been evaluated in studies, including a rigorous study from
Minnesota, USA, that demonstrated that noncompliant patients
lose grafts more readily [29], most likely due to the initiation of
1468 Pediatr Nephrol (2009) 24:1465–1471subclinicalchronicimmuneinjuryduringanoncompliantperiod
leading to CAN development and permanent nephron loss.
Subclinical rejection
Subclinical rejection is the histological presence of immuno-
reactive cells within the kidney allograft suggestive of acute
rejection without clinical deterioration of renal function; i.e.
renal function remains stable. Untreated SCR can lead to the
development of overt ACR with graft dysfunction or may
smoulder on to eventual CAN. The incidence of subclinical
inflammatory infiltrates of 35–53% [18, 42]i np r o t o c o l
biopsies at 3 months post paediatric kidney transplants are
similar to adult reports [11], and both groups of patients
show reduction in SCR rates by 12–18 months [11, 42].
In paediatric transplant recipients with large kidney grafts
and increased early GFR proportionate to size, nonimmune
rejection processes may be advanced before functional
changes are detected by serum creatinine measurement [20],
leading to ongoing debate on the need for protocol biopsies
in children, which is discussed below. However, the rates of
SCR are lower with modern immunosuppression, so that it is
unclear whether the advantage of increasing immunosup-
pressive treatment is outweighed by infectious risks.
Protocol biopsies
Protocol biopsies can be performed after transplantation to detect
early subclinical rejection, signs of CAN or CNI nephropathy
and to monitor graft anatomy in children with stable renal
function.Althoughnotroutineclinical practiceinpaediatricrenal
transplantation, they have been performed as part of a number of
clinical studies [43]. Recent reports confirm the safety of this
procedure [44]. The incidence of CAN in paediatric protocol
biopsy cohorts ranged from 30% to 100% by 2 years
posttransplant [17–19, 21, 22], which supports a potential role
in routine practice that may influence treatment. SCR treatment
in adults and children involving high-dose pulse corticosteroids
is supported yet not proven in cohort studies showing the
reduction of histological changes in CAN [45] or its stabilisation
[46–48]. ThebenefitsoftreatingSCR,however,andthestrength-
ening of immunosuppression that is usually required, need to be
weighed against the increased risk of primary infection, viral
reactivation such as CMV, BK and EBV, and PTLD.
Newer ways of identifying and classification of CAN
Improvements in the use of molecular genetics through gene
expression arrays and an increased ability to identify variabil-
ity in genes by genome-wide or molecular pathway-specific
arrays suggest that we may be able to move to a molecular
classification of allograft damage at some point. It may be that
genetic differences in both recipient and donor are important,
and identifying these factors in both may allow us to view not
just disease progression but possibly predict and modify risk.
Despite the variability in results from genomics, proteomics
and expression arrays, a recent review of the Banff classifica-
tion (Banff 05) led to support for consideration of a broader
range of aetiologies and the potential for a genomics-
supported classification [49]. This is an evolving process to
provide more consistent evaluation of renal biopsies leading
to improved diagnostic and therapeutic outcomes. [50].
New therapies
A number of new agents have been tested in adults and
children, including sirolimus, everolimus, FTY720 and
protocols that use high levels of immunosuppression early to
reduce long-term immunosuppression either by discontinuing
steroids or discontinuing CNIs using anti-interleukin-2R (IL-
2R) antibodies or immune-depleting antibodies such as
Campath. Other new agents include the new CTLA4-Ig
antibody belatacept, which has been used successfully in
place of CNIs in adult studies of kidney transplantation [51]
and the Janus kinase (JAK) inhibitors.
Success of standard treatment limits the ability to assess
new agents, and the lack of good surrogate markers for
transplant damage make evaluation of the different regimes
difficult. There are also a number of new agents under
development to prevent fibrosis, such as bone morphologic
protein-7(BMP-7)thatmaylimitnonimmunerenalinjuryand
may have a place in renal transplants to extend survival.
In summary, CAN is a major cause of paediatric graft loss.
There are both donor and recipient causes for this, and it is
likely that it reflects a combination of both immune and
nonimmune injury occurring cumulatively over time. Histo-
logical features of CAN and specific features that suggest the
underlying aetiology are under regular revision. Protocol
biopsies in children and management of SCR or early CAN
with immunosuppression adjustment may potentially slow
CAN progression but must be weighed against the more
general risks of over- or underimmunosuppression.
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Questions
(Answers appear after the reference list.)
1. Which of the following is not a histopathological feature
of CAN?
a. Interstitial fibrosis
b. Tubular atrophy
c. Glomerulosclerosis
Pediatr Nephrol (2009) 24:1465–1471 1469d. Striped fibrosis
e. Fibrointimal hyperplasia
2. Which of the following is not an infection that has been
shown to increase progression to CAN?
a. Cytomegalovirus
b. Epstein-Barr Virus
c. Coxsackie virus (enterovirus)
d. Polyoma virus
e. BK virus
3. Calcineurin toxicity induceswhichone of the following to
potentiaterenalfibrosisandeventualprogressiontoCAN?
a. TNF-α
b. VEGF
c. TGF-β
d. STAT 4
e. STAT 6
4. The addition of which one of the following leads to the
improvement in diagnosing humoral-mediated rejection
on renal biopsy?
a. C4d
b. C3
c. C4
d. C50
e. C1q
5. Donor factors associated with increased risk for the
development of CAN include all of the following except?
a. Young age
b. Male sex
c. HLA mismatch
d. Large allograft size in small recipients
e. Prolonged cold ischaemia time
6. Subclinical rejection (SCR) is diagnosed by:
a. Clinically by a raised creatinine
b. Identification of molecular markers in the urine
c. Number of T cells present in the urine assessed by
flow cytometry
d. Crystal ball
e. Histopathologically with stable renal function
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